An AI Platform integrating imaging data and models, supporting precision care through prostate cancer’s continuum
Editorial by Prof Manolis Tsiknakis, Coordinator of ProCAncer-I project The ProCAncer-I consortium welcomes you to our first newsletter! We are very happy that our project ProCAncer-I on dealing with prostate cancer was funded by the EU and that through its successful...
Βy Prof. Daniele Regge [Chief of the Radiology Unit, Candiolo Cancer Institute, Torino-Italy] and Simone Mazzetti [Candiolo Cancer Institute, Torino-Italy] Prostate cancer is the most frequently diagnosed tumour in Europe with one new cancer detected every...
Βy Prof Kostas Marias [Foundation for Research and Technology - Hellas (FORTH)], Ioannis Karatzanis [Foundation for Research and Technology - Hellas (FORTH)] and Katerina Nikiforaki [Foundation for Research and Technology - Hellas (FORTH)] Anonymization is an...
Βy Nickolas Papanikolaou [Principal Investigator in Oncologic Imaging at the Fundação Champalimaud] Why did you select prostate cancer as the center of your research? What kind of clinical unmet needs will be addressed in ProCancer-I? Prostate cancer is among the most...
By the legal team of ProCAncer-I, The University of Vienna Department of Innovation and Digitalisation in Law (UNIVIE) Given the innovative nature of the technology being developed in the ProCAncer-I project, complex legal questions have arisen concerning the...
By the Radboud UMC Radboudumc is one of the leading centres for prostate cancer imaging worldwide. Within the ProCAncer-I project, two groups of the Department of Imaging of Radboudumc are represented. The Diagnostic Image Analysis Group (DIAG), under the...
By the University of Vienna – Department of Innovation and Digitalisation in Law (UNIVIE) The University of Vienna is the oldest University in the German-speaking world, and the Department of Innovation and Digitalisation in Law is the newest addition to the...
Newsletter #1 Contents
We are looking forward to participating it the upcoming IEEE-MeMeA Conference in Taormina! The 17th edition of IEEE International Symposium on Medical Measurements and Applications will take place in Giardini Naxos, Taormina in the metropolitan area of Messina,...
We are really happy to announce that we will be present at the ECR Congress in Vienna on 13 - 17 of July 2022. During the congress, a special Session will take place on the 15th of July, presenting and discussing on the ProCAncer-I project with the title: Building...
The European Union is actively working on improving the digital environment for the benefit of all Europeans. Professor Tsiknakis took part in a recent feature in the EU Council site on how the EU protects users online, ensures cybersecurity and facilitates the...
Nowadays, prostate cancer is highly curable if detected in its early stages. Indeed, when organ-confined at diagnosis, the five-year survival rate of prostate cancer is close to 100%. Unfortunately, current prostate cancer diagnostic pipeline has several limitations. Prostate specific antigen (PSA) has a low sensitivity and specificity.